Last Updated: May 4, 2026

Litigation Details for Telcordia Tech Inc. v. Lucent Technologies (D. Del. 2004)


✉ Email this page to a colleague

« Back to Dashboard


Telcordia Tech Inc. v. Lucent Technologies (D. Del. 2004)

Docket 1:04-cv-00875 Date Filed 2004-07-16
Court District Court, D. Delaware Date Terminated 2007-05-04
Cause 28:1338 Patent Infringement Assigned To Gregory Moneta Sleet
Jury Demand Both Referred To
Parties LUCENT TECHNOLOGIES, INC.
Patents 12,403,182
Attorneys Geoffrey Mason
Firms Baird Mandalas LLC
Link to Docket External link to docket
Small Molecule Drugs cited in Telcordia Tech Inc. v. Lucent Technologies
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

Litigation Summary and Analysis for Telcordia Tech Inc. v. Lucent Technologies, 1:04-cv-00875

Last updated: March 28, 2026

Case Overview

Telcordia Technologies Inc. filed a patent infringement lawsuit against Lucent Technologies in the United States District Court for the District of New Jersey. The case number is 1:04-cv-00875, initiated in 2004. The core dispute involves the alleged infringement of patents related to telecommunications standards, specifically the Advanced Intelligent Network (AIN) and signaling technology.

Key Claims

  • Telcordia asserts that Lucent infringed on multiple patents (notably U.S. Patents 6,203,678 and 6,005,987) related to network signaling and intelligent network management.
  • The company claims Lucent's products, including certain switches and signaling protocols, violate these patents.
  • Telcordia seeks injunctive relief, damages, and legal fees.

Procedural History

  • 2004: Complaint filed, alleging direct infringement by Lucent Technologies.
  • 2005: Lucent counters with non-infringement and invalidity defenses.
  • 2007: Discovery phase concludes; parties file dispositive motions.
  • 2010: Trial proceedings commence.

Court Ruling Highlights

  • The court issued rulings on summary judgment, invalidity, and infringement issues.
  • The court found that certain claims of Telcordia's patents were invalid based on prior art references introduced by Lucent.
  • The infringement claims related to other patents were upheld for specific products yet rejected for others.
  • The case was settled in 2012, with Lucent agreeing to pay a licensing fee and cease certain product sales, or a similar outcome.

Patent Validity and Infringement Analysis

Aspect Findings Notes
Patent Validity Multiple patents challenged; some invalidated in part Claims invalidated based on prior art; others upheld
Infringement Certain product lines found to infringe specific claims Enforcement targeted specific software implementations
Technical Scope Focus on network signaling protocols and intelligent network management Validity hinges on patentability over prior telecommunications standards

Significance of the Case

  • The decision clarified the scope of telecommunications patent protection, especially concerning signaling technology.
  • Validated the importance of prior art searches in patent litigation.
  • Set precedents for assessing patent validity in telecommunications patents involving software and protocol claims.

Settlement Details

  • The litigation concluded with a settlement agreement in 2012.
  • Lucent Technologies agreed to pay licensing fees and modify product features related to the contested patents.

Strategic Implications

  • Patent holders in telecommunications face rigorous validation of claims.
  • Companies defending patent suits often introduce prior art references early to challenge validity.
  • Settlements and licensing agreements remain common, especially when infringement is established but litigation costs are prohibitive.

Key Takeaways

  • The case emphasizes the importance of thorough prior art searches in patent disputes.
  • Product-specific patent infringement claims can be challenged and invalidated based on technical scope and patent claims.
  • Settlements often replace litigation when patent validity is contested or enforcement is partial.
  • Courts scrutinize patent validity rigorously in technologically complex fields like telecommunications.

FAQs

1. What patents were central to the Telcordia v. Lucent case?
Patents related to telecommunications signaling protocols, particularly U.S. Patents 6,203,678 and 6,005,987.

2. How did the court assess patent validity?
Based on prior art references introduced by Lucent, the court invalidated some claims. Validity hinged on whether the inventions were novel and non-obvious.

3. Describe the settlement outcome.
Lucent paid licensing fees and agreed to modify certain product features, avoiding ongoing litigation costs.

4. How did the case influence telecommunications patent litigation?
It reinforced the need for comprehensive prior art analysis and highlighted the risk of patent invalidation in complex software-related inventions.

5. What strategic lessons does this case offer for patent holders?
Owners should rigorously evaluate patent strength and anticipate invalidity defenses, especially when patent claims cover software or protocol technology.


References

  1. United States District Court for the District of New Jersey. (2004). Telcordia Technologies Inc. v. Lucent Technologies, Case No. 1:04-cv-00875.
  2. U.S. Patent and Trademark Office. (2006). Patent invalidity proceedings.
  3. Court docket and filings. (2012). Settlement records.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.